Acrivon Therapeutics, Inc.

Analysis for Ticker: ACRV

Acrivon Therapeutics Inc is a precision oncology business that uses a platform called AP3 to analyze protein signaling in tumors to find patients who might respond to its experimental drugs. The clinical reality is a financial incinerator that has amassed an accumulated deficit of 274,9$ million without ever selling a single product. This company operates as a wealth transfer machine where the public provides cash to fund a clinical trial while the insiders use that same equity to pay their personal tax bills. It is like a group of people asking you to fund a lemonade stand that has no lemons and no customers, but they keep taking some of your money to pay for their own chores at home.